Standard and biological treatment in large vessel vasculitis: guidelines and current approaches

ABSTRACT

Introduction: Giant cell arteritis and Takayasu arteritis are the two major forms of idiopathic large vessel vasculitis. High doses of glucocorticoids are effective in inducing remission in both conditions, but relapses and recurrences are common, requiring prolonged glucocorticoid treatment with the risk of the related adverse events.

Areas covered: In this article, we will review the standard and biological treatment strategies in large vessel vasculitis, and we will focus on the current approaches to these diseases.

Expert commentary: The results of treatment trials with conventional immunosuppressive agents such as methotrexate, azathioprine, mycophenolate mofetil, and cyclophosphamide have overall been disappointing. TNF-α blockers are ineffective in giant cell arteritis, while observational evidence and a phase 2 randomized trial support the use of tocilizumab in relapsing giant cell arteritis. Observational evidence strongly supports the use of anti-TNF-α agents and tocilizumab in Takayasu patients with relapsing disease. However biological agents are not curative, and relapses remain common.

KEYWORDS:

• Large vessel vasculitis
• Takayasu arteritis
• giant cell arteritis
• treatment
• biological agents
• anti-TNF-α
• tocilizumab
• immunosuppressive agents

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

References

• Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1–11.
   PubMed Web of Science ®Google Scholar
• Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine (Baltimore). 2009;88:221–226.
   PubMed Web of Science ®Google Scholar
• Polachek A, Pauzner R, Levartovsky D, et al. The fine line between Takayasu arteritis and giant cell arteritis. Clin Rheumatol. 2015;34:721–727.
   PubMed Web of Science ®Google Scholar
• Grayson PC, Maksimowicz-McKinnon K, Clark TM, et al. Distribution of arterial lesions in Takayasu’s arteritis and giant cell arteritis. Ann Rheum Dis. 2012;71:1329–1334.
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68:318–323.
   PubMed Web of Science ®Google Scholar
• Pipitone N, Salvarani C. Improving therapeutic options for patients with giant cell arteritis. Curr Opin Rheumatol. 2008;20:17–22.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372:234–245.
   PubMed Web of Science ®Google Scholar
• Swannell AJ. Polymyalgia rheumatica and temporal arteritis: diagnosis and management. BMJ. 1997;314:1329–1332.
   PubMed Web of Science ®Google Scholar
• Sailler L, Carreiro M, Ollier S, et al. Noncomplicated Horton’s disease: initial treatment with methylprednisolone 500 mg/day bolus for three days followed by 20 mg/day prednisone-equivalent: evaluation of 15 patients. Rev Med Interne. 2001;22:1032–1038.
   PubMed Web of Science ®Google Scholar
• Chevalet P, Barrier JH, Pottier P, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol. 2000;27:1484–1491.
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Zimmerman B. Management of giant cell arteritis: our 27-year clinical study: new light on old controversies. Ophthalmologica. 2003;217:239–259.
   PubMed Web of Science ®Google Scholar
• Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54:3310–3318.
   PubMed Web of Science ®Google Scholar
• Hunder GG, Sheps SG, Allen GL, et al. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med. 1975;82:613–618.
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49:1594–1597.
   PubMed Web of Science ®Google Scholar
• Proven A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003;49:703–708.
   PubMed Web of Science ®Google Scholar
• Muratore F, Pipitone N, Hunder GG, et al. Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis. Clin Exp Rheumatol. 2013;31(4 Suppl 78):S86–S92.
   PubMed Web of Science ®Google Scholar
• Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med. 1994;120:919–929.
   PubMed Web of Science ®Google Scholar
• Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol. 2005;17:16–24.
   PubMed Web of Science ®Google Scholar
• Ferfar Y, Mirault T, Desbois AC, et al. Biotherapies in large vessel vasculitis. Autoimmun Rev. 2016;15:544–551.
   PubMed Web of Science ®Google Scholar
• Spiera RF, Mitnick HJ, Kupersmith M, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19:495–501.
   PubMed Web of Science ®Google Scholar
• Jover JA, Hernandez-Garcia C, Morado IC, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:106–114.
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46:1309–1318.
   PubMed Web of Science ®Google Scholar
• Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate to treat giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2006;56:2789–2797.
   Web of Science ®Google Scholar
• Bienvenu B, Ly KH, Lambert M, et al. Management of giant cell arteritis: recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Rev Med Interne. 2016;37:154–165.
   PubMed Web of Science ®Google Scholar
• De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis. 1986;45:136–138.
   PubMed Web of Science ®Google Scholar
• Schaufelberger C, Möllby H, Uddhammar A, et al. No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. Scand J Rheumatol. 2006;35:327–329.
   PubMed Web of Science ®Google Scholar
• Sailler L, Lapeyre-Mestre M, Geffray L, et al. Hydroxychloroquine to prednisone does not improve the outcome in giant cell arteritis: a double blind randomized controlled trial [abstract]. Arthritis Rheum. 2009;60(Suppl. 10):1972.
   Google Scholar
• Adizie T, Christidis D, Dharmapaliah C, et al. Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series. Int J Clin Pract. 2012;66:906–909.
   PubMed Web of Science ®Google Scholar
• Diamantopoulos AP, Hetland H, Myklebust G. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int. 2013;2013:1–3.
   Web of Science ®Google Scholar
• Sciascia S, Piras D, Baldovino S, et al. Mycophenolate mofetil as steroid-sparing treatment for elderly patients with giant cell arteritis: report of three cases. Aging Clin Exp Res. 2012;24:273–277.
   Google Scholar
• Loock J, Henes J, Kötter I, et al. Treatment of refractory giant cell arteritis with cyclophosphamide: a retrospective analysis of 35 patients from three centres. Clin Exp Rheumatol. 2012;30(1 Suppl 70):S70–S76.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Maset M, De Maglio G, et al. Role of oral cyclophosphamide in the treatment of giant cell arteritis. Rheumatology (Oxford). 2012;51:1677–1686.
   PubMed Web of Science ®Google Scholar
• de Boysson H, Boutemy J, Creveuil C, et al. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review. Semin Arthritis Rheum. 2013;43:105–112.
   PubMed Web of Science ®Google Scholar
• Keser G, Direskeneli H, Aksu K. Management of Takayasu arteritis: a systematic review. Rheumatology (Oxford). 2014;53:793–801.
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Leavitt RY, Kerr GS, et al. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum. 1994;37:578–582.
   PubMed Web of Science ®Google Scholar
• Valsakumar AK, Valappil UC, Jorapur V, et al. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu’s arteritis. J Rheumatol. 2003;30:1793–1798.
   PubMed Web of Science ®Google Scholar
• Shinjo SK, Pereira RM, Tizziani VA, et al. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin Rheumatol. 2007;26:1871–1875.
   PubMed Web of Science ®Google Scholar
• Goel R, Danda D, Mathew J, et al. Mycophenolate mofetil in Takayasu’s arteritis. Clin Rheumatol. 2010;29:329–332.
   PubMed Web of Science ®Google Scholar
• Shelhamer JH, Volkman DJ, Parrillo JE, et al. Takayasu’s arteritis and its therapy. Ann Intern Med. 1985;103:121–126.
   PubMed Web of Science ®Google Scholar
• Talwar KK, Chopra P, Narula J, et al. Myocardial involvement and its response to immunosuppressive therapy in nonspecific aortoarteritis (Takayasu’s disease)—a study by endomyocardial biopsy. Int J Cardiol. 1988;21:323–334.
   PubMed Web of Science ®Google Scholar
• de Souza AW, da Silva MD, Machado LS, et al. Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. Scand J Rheumatol. 2012;41:227–230.
   PubMed Web of Science ®Google Scholar
• Field M, Cook A, Gallagher G. Immuno-localisation of tumour necrosis factor and its receptors in temporal arteritis. Rheumatol Int. 1997;17:113–118.
   PubMed Web of Science ®Google Scholar
• Hernandez-Rodriguez J, Segarra M, Vilardell C, et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford). 2004;43:294–301.
   PubMed Web of Science ®Google Scholar
• Samson M, Audia S, Janikashvili N, et al. Is TNF-α really involved in giant cell arteritis pathogenesis? Ann Rheum Dis. 2014;73(1):e1.
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146:621–630.
   PubMed Web of Science ®Google Scholar
• Seror R, Baron G, Hachulla E, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis. 2013;73:2074–2081.
   PubMed Web of Science ®Google Scholar
• Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis. 2008;67:625–630.
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Salvarani C, et al. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum. 2001;44:2933–2935.
   PubMed Web of Science ®Google Scholar
• Andonopoulos AP, Meimaris N, Daoussis D, et al. Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis. 2003;62:1116.
   PubMed Web of Science ®Google Scholar
• Ahmed MM, Mubashir E, Hayat S, et al. Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol. 2007;26:1353–1355.
   PubMed Web of Science ®Google Scholar
• Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med. 1994;121:484–491.
   PubMed Web of Science ®Google Scholar
• Emilie D, Liozon E, Crevon MC, et al. Production of interleukin 6 by granulomas of giant cell arteritis. Hum Immunol. 1994;39:17–24.
   PubMed Web of Science ®Google Scholar
• García-Martínez A, Hernández-Rodríguez J, Espígol-Frigolé G, et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis. Arthritis Care Res (Hoboken). 2010;62:835–841.
   PubMed Web of Science ®Google Scholar
• Weyand CM, Fulbright JW, Hunder GG, et al. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum. 2000;43:1041–1048.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Magnani L, Catanoso M, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford). 2012;51:151–156.
   PubMed Web of Science ®Google Scholar
• Seitz M, Reichenbach S, Bonel HM, et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly. 2011;141:w13156.
   PubMed Web of Science ®Google Scholar
• Sciascia S, Rossi D, Roccatello D. Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis. J Rheumatol. 2011;38:2080–2081.
   PubMed Web of Science ®Google Scholar
• Beyer C, Axmann R, Sahinbegovic E, et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis. 2011;70:1874–1875.
   PubMed Web of Science ®Google Scholar
• Vinit J, Bielefeld P, Muller G, et al. Efficacy of tocilizumab in refractory giant cell arteritis. Joint Bone Spine. 2012;79:317–318.
   PubMed Web of Science ®Google Scholar
• Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken). 2012;64:1720–1729.
   PubMed Web of Science ®Google Scholar
• Besada E, Nossent JC. Ultrasonographic resolution of the vessel wall oedema with modest clinical improvement in a large-vessel vasculitis patient treated with tocilizumab. Clin Rheumatol. 2012;31:1263–1265.
   PubMed Web of Science ®Google Scholar
• Christidis D, Jain S, Das Gupta B. Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement. BMJ Case Rep. 2011. pii: bcr0420114135.
   PubMedGoogle Scholar
• Pazzola G, Padovano I, Boiardi L, et al. Tocilizumab in glucocorticoid-naïve large-vessel vasculitis. Clin Exp Rheumatol. 2013;31:S59–61.
   PubMed Web of Science ®Google Scholar
• Régent A, Redeker S, Deroux A, et al. Tocilizumab in giant cell arteritis: a multicentre retrospective study of 34 patients. J Rheumatol. 2016;43:1547–1552.
   Web of Science ®Google Scholar
• Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:1921–1927.
   PubMed Web of Science ®Google Scholar
• Adler S, Reichenbach S, Kuchen S, et al. Termination of tocilizumab-treatment in giant cell arteritis: follow-up of patients after the RCT (ClinicalTrials.gov registration number: NCT01450137) [abstract]. Arthritis Rheumatol. 2016;68(suppl 10).
   Google Scholar
• Stone JH, Tuckwell K, Dimonaco S, et al. Efficacy and safety of tocilizumab in patients with giant cell arteritis: primary and secondary outcomes from a phase 3, randomized, double-blind, placebo-controlled trial [abstract]. Arthritis Rheumatol. 2016;68(suppl 10).
   Google Scholar
• Ly KH, Stirnemann J, Liozon E, et al. Interleukin-1 blockade in refractory giant cell arteritis. Joint Bone Spine. 2014;81:76–78.
   PubMed Web of Science ®Google Scholar
• Koster MJ, Matteson EL, Warrington KJ. Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis. Curr Opin Rheumatol. 2016;28:211–217.
   PubMed Web of Science ®Google Scholar
• Conway R, O’Neill L, O’Flynn E, et al. Ustekinumab for the treatment of refractory giant cell arteritis. Ann Rheum Dis. 2016;75:1578–1579.
   PubMed Web of Science ®Google Scholar
• Langford C, Cuthbertson D, Ytterberg S, et al. A randomized double-blind trial of abatacept and glucocorticoids for the treatment of giant cell arteritis [abstract]. Arthritis Rheumatol. 2015;67(suppl 10).
   Google Scholar
• Hoffman GS, Merkel PA, Brasington RD, et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. 2004;50:2296–2304.
   PubMed Web of Science ®Google Scholar
• Molloy ES, Langford CA, Clark TM, et al. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis. 2008;67:1567–1569.
   PubMed Web of Science ®Google Scholar
• Schmidt J, Kermani TA, Bacani AK, et al. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup. Arthritis Care Res (Hoboken). 2012;64:1079–1083.
   PubMed Web of Science ®Google Scholar
• Clifford A, Hoffman GS. Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies. Curr Opin Rheumatol. 2014;26:7–15.
   PubMed Web of Science ®Google Scholar
• Mekinian A, Comarmond C, Resche-Rigon M, et al. Efficacy of biological-targeted treatments in Takayasu arteritis: multicenter, retrospective study of 49 patients. Circulation. 2015;132:1693–1700.
   PubMed Web of Science ®Google Scholar
• Seko Y, Sato O, Takagi A, et al. Restricted usage of T-cell receptor Valpha-Vbeta genes in infiltrating cells in aortic tissue of patients with Takayasu’s arteritis. Circulation. 1996;93:1788–1790.
   PubMed Web of Science ®Google Scholar
• Noris M, Daina E, Gamba S, et al. Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation. 1999;100:55–60.
   PubMed Web of Science ®Google Scholar
• Park MC, Lee SW, Park YB, et al. Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis. Rheumatology (Oxford). 2006;45:545–548.
   PubMed Web of Science ®Google Scholar
• Goel R, Danda D, Kumar S, et al. Rapid control of disease activity by tocilizumab in 10 ‘difficult-to-treat’ cases of Takayasu arteritis. Int J Rheum Dis. 2013;16:754–761.
   PubMed Web of Science ®Google Scholar
• Xenitidis T, Horger M, Zeh G, et al. Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis. Rheumatology (Oxford). 2013;52:1729–1731.
   PubMed Web of Science ®Google Scholar
• Tombetti E, Franchini S, Papa M, et al. Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center. J Rheumatol. 2013;40:2047–2051.
   PubMed Web of Science ®Google Scholar
• Bredemeier M, Rocha CM, Barbosa MV, et al. One-year clinical and radiological evolution of a patient with refractory Takayasu’s arteritis under treatment with tocilizumab. Clin Exp Rheumatol. 2012;30(1 Suppl 70):S98–S100.
   PubMed Web of Science ®Google Scholar
• Sieper J, Porter-Brown B, Thompson L, et al. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis. 2014;73:95–100.
   PubMed Web of Science ®Google Scholar
• Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomized, double-blind, placebo-controlled, phase 3 trial in Japan [abstract]. Arthritis Rheumatol. 2016;68(suppl 10).
   Google Scholar
• Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized double-blind trial of abatacept and glucocorticoids for the treatment of Takayasu’s arteritis [abstract]. Arthritis Rheumatol. 2016;68(suppl 10).
   Google Scholar
• Inder SJ, Bobryshev YV, Cherian SM, et al. Immunophenotypic analysis of the aortic wall in Takayasu’s arteritis: involvement of lymphocytes, dendritic cells and granulocytes in immuno-inflammatory reactions. Cardiovasc Surg. 2000;8:141–148.
   PubMedGoogle Scholar
• Hoyer BF, Mumtaz IM, Loddenkemper K, et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis. 2012;71:75–79.
   PubMed Web of Science ®Google Scholar
• Caltran E, Di Colo G, Ghigliotti G, et al. Two Takayasu arteritis patients successfully treated with rituximab. Clin Rheumatol. 2014;33:1183–1184.
   PubMed Web of Science ®Google Scholar
• Muratore F, Cavazza A, Boiardi L, et al. Histopathologic findings of patients with biopsy-negative giant cell arteritis compared to those without arteritis: a population-based study. Arthritis Care Res (Hoboken). 2016;68:865–870.
   PubMed Web of Science ®Google Scholar
• Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004;50:1332–1337.
   PubMed Web of Science ®Google Scholar
• Lee MS, Smith SD, Galor A, et al. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 2006;54:3306–3309.
   PubMed Web of Science ®Google Scholar
• Narváez J, Bernad B, Gómez-Vaquero C, et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol. 2008;26(3Suppl 49):S57–S62.
   Google Scholar
• Gonzalez-Gay MA, Piñeiro A, Gomez-Gigirey A, et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore). 2004;83:342–347.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Della Bella C, Cimino L, et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford). 2009;48:250–253.
   PubMed Web of Science ®Google Scholar
• Berger CT, Wolbers M, Meyer P, et al. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology (Oxford). 2009;48:258–261.
   PubMed Web of Science ®Google Scholar
• Martínez-Taboada VM, López-Hoyos M, Narvaez J, et al. Effect of antiplatelet/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: a cumulative meta-analysis. Autoimmun Rev. 2014;13:788–794.
   PubMed Web of Science ®Google Scholar
• Pipitone N, Olivieri I, Salvarani C. Recommendations of the Italian Society of Rheumatology for the treatment of the primary large-vessel vasculitis with biological agents. Clin Exp Rheumatol. 2012;30(1 Suppl 70):S139–S161.
   Google Scholar

Additional information

Funding

This article was not funded.